Eqis Capital Management, Inc. Corcept Therapeutics Inc Transaction History

Eqis Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$19.97 - $24.43 $183,604 - $224,609	-9,194 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$23.49 - $30.56 $215,967 - $280,968	9,194 New	9,194 $219,000
Q4 2020 Feb 11, 2021	SELL	$16.78 - $27.3 $220,808 - $359,240	-13,159 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$12.46 - $19.98 $163,961 - $262,916	13,159 New	13,159 $229,000
Q1 2019 Apr 18, 2019	SELL	$10.03 - $15.71 $284,430 - $445,504	-28,358 Closed	0 $0
Q4 2018 Jan 25, 2019	SELL	$11.29 - $17.19 $26,452 - $40,276	-2,343 Reduced 7.63%	28,358 $379,000
Q3 2018 Oct 17, 2018	BUY	$12.27 - $15.65 $63,202 - $80,613	5,151 Added 20.16%	30,701 $461,000
Q2 2018 Jul 27, 2018	BUY	$15.3 - $19.69 $390,915 - $503,079	25,550 New	25,550 $402,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.3B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.